Table 3 Cox univariate and multivariable analysis for recurrence free period (RFP) for combined expression of MIC-AB and ULBP-2.

Age

< 40

48

1.00

0.422

40-50

145

0.97

0.612-1.539

50-60

132

1.17

0.734-1.853

> 60

249

0.90

0.574-1.408

Grade

I

80

1.00

0.001

1.00

0.473

II

282

1.43

0.945-2.172

1.18

0.711-1.948

III

203

2.02

1.326-3.078

1.34

0.802-2.231

Histological type

Ductal

513

1.00

0.291

Other

53

1.24

0.832-1.846

Tumor stage

pT1

211

1.00

< 0.001

1.00

0.298

pT2

272

1.59

1.205-2.093

1.17

0.832-1.637

pT3/4

72

2.49

1.706-3.635

1.45

0.908-2.316

Nodalstage

pN-

307

1.00

< 0.001

1.00

< 0.001

pN+

250

3.06

2.379-3.945

2.70

1.987-3.669

ER-status

Negative

203

1.00

0.725

Positive

337

1.05

0.808-1.359

PgR-status

Negative

223

1.00

0.744

Positive

313

0.96

0.743-1.236

HER2

No overexpression

378

1.00

0.401

Overexpression

44

1.21

0.776-1.883

Endocrine therapy

ET-

481

1.00

0.197

ET+

93

1.24

0.896-1.705

Chemotherapy

CT-

444

1.00

0.839

CT+

130

0.97

0.730-1.291

MIC-AB & ULBP-2

Both Low

68

1.00

< 0.001

1.00

< 0.001

Either one high

275

0.59

0.426-0.820

0.54

0.380-0.757

Both high

64

0.38

0.230-0.612

0.41

0.246-0.682